PSP Ferroptosis and Iron-Dependent Cell Death

PSP Ferroptosis and Iron-Dependent Cell Death

Introduction

Ferroptosis is a regulated form of non-apoptotic cell death characterized by iron-dependent accumulation of lipid peroxides, distinct from apoptosis, necroptosis, and pyroptosis. First described in 2012, ferroptosis has emerged as a critical pathway in neurodegenerative diseases, including the 4R-tauopathies such as progressive supranuclear palsy (PSP). The disease's prominent iron accumulation in the basal ganglia, combined with evidence of lipid peroxidation and antioxidant system alterations, makes ferroptosis a highly relevant yet underexplored mechanism in PSP pathogenesis. PMID: 39721496

This page synthesizes evidence for ferroptosis as a cell death mechanism in PSP, covering the molecular pathways, iron metabolism dysregulation, lipid peroxidation cascades, and therapeutic implications. PMID: 35047897

PSP Ferroptosis and Iron-Dependent Cell Death

Introduction

Ferroptosis is a regulated form of non-apoptotic cell death characterized by iron-dependent accumulation of lipid peroxides, distinct from apoptosis, necroptosis, and pyroptosis. First described in 2012, ferroptosis has emerged as a critical pathway in neurodegenerative diseases, including the 4R-tauopathies such as progressive supranuclear palsy (PSP). The disease's prominent iron accumulation in the basal ganglia, combined with evidence of lipid peroxidation and antioxidant system alterations, makes ferroptosis a highly relevant yet underexplored mechanism in PSP pathogenesis. PMID: 39721496

This page synthesizes evidence for ferroptosis as a cell death mechanism in PSP, covering the molecular pathways, iron metabolism dysregulation, lipid peroxidation cascades, and therapeutic implications. PMID: 35047897

Ferroptosis Overview

Definition and Key Features

Ferroptosis is an iron-catalyzed, non-apoptotic cell death pathway driven by the accumulation of lipid peroxides, particularly phosphatidylethanolamine (PE) containing polyunsaturated fatty acids (PUFAs). The process requires:

• Iron (Fe²⁺): Catalyzes the Fenton reaction, generating hydroxyl radicals from hydrogen peroxide
• Lipid substrates: PUFA-containing phospholipids in membrane bilayers
• Loss of lipid repair capacity: Inactivation of glutathione peroxidase 4 (GPX4) or system Xc⁻ cystine/glutamate antiporter
• Peroxidation cascade: Iron-dependent propagation of lipid radical formation

Distinction from Other Cell Death Types

| Feature | Ferroptosis | Apoptosis | Necroptosis | Pyroptosis |
|---------|-------------|-----------|-------------|------------|
| Morphology | Shrunken mitochondria, intact nucleus | Chromatin condensation, apoptotic bodies | Cellular swelling, membrane rupture | Cell swelling, membrane pore formation |
| Mechanism | Iron-dependent | Caspase-dependent | RIPK1/3-dependent | Caspase-1/4-dependent |
| Biochemistry | Lipid peroxide accumulation | DNA fragmentation | MLKL phosphorylation | IL-1β/IL-18 release |
| Inhibition | Iron chelators, lipophilic antioxidants | Caspase inhibitors | RIPK1 inhibitors | Caspase-1 inhibitors |

Iron Metabolism in PSP

Pattern of Iron Accumulation

PSP exhibits striking patterns of iron accumulation in specific brain regions:

• Globus pallidus internus (GPi): Most severely affected, with marked iron deposition
• Subthalamic nucleus: High iron levels correlating with neuronal loss
• Substantia nigra pars reticulata (SNr): Iron accumulation in pigmented neurons
• Red nucleus: Moderate iron deposition
• Brainstem nuclei: Varying degrees of iron accumulation

Molecular Mechanisms of Iron Dysregulation

The iron accumulation in PSP results from multiple mechanisms:

1. Dysregulated Iron Transport Proteins

• Ferroportin (FPN): Decreased expression on neuronal and glial membranes reduces iron export
• Transferrin receptor (TfR1): Altered expression affects cellular iron uptake
• Divalent metal transporter 1 (DMT1): Increased expression may promote iron influx
• Ferritin: Altered heavy (FTH) and light (FTL) chain expression affects iron storage

2. Iron Regulatory Proteins

• IRP/IRE system: Dysregulation of iron regulatory protein binding affects transferrin and ferritin synthesis
• Hepcidin: Altered expression may affect systemic iron homeostasis

3. Mitochondrial Iron Handling

• Mitochondrial ferritin (FtMt): Increased expression in PSP neurons suggests compensatory response
• Iron-sulfur cluster assembly: Impaired ISCU function affects mitochondrial iron metabolism

Clinical Correlation

The regional distribution of iron accumulation in PSP correlates with:

• Motor dysfunction: GPi and SNr iron levels correlate with bradykinesia and rigidity
• Ocular motor deficits: Superior colliculus iron accumulation relates to vertical gaze palsy
• Postural instability: Brainstem nuclei iron levels correlate with falls

Lipid Peroxidation in PSP

Evidence of Lipid Peroxidation

Multiple lines of evidence support increased lipid peroxidation in PSP:

• 4-hydroxynonenal (4-HNE): Elevated in PSP brain tissue and CSF
• Malondialdehyde (MDA): Increased in PSP post-mortem brain tissue
• F₂-isoprostanes: Elevated in CSF of PSP patients
• 8-oxoguanosine: Increased in mitochondrial DNA from PSP substantia nigra

Lipid Peroxidation Cascades

The Fenton Reaction

Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻ (Haber-Weiss reaction)
Fe³⁺ + LOOH → Fe²⁺ + LOO• + H⁺ (Fenton-like reaction)

The iron-catalyzed generation of hydroxyl radicals initiates lipid peroxidation:

Lipid Radical Propagation

Membrane Vulnerability

Neurons in PSP show particular vulnerability to lipid peroxidation due to:

• High PUFA content: Neuronal membranes rich in arachidonic acid (AA) and docosahexaenoic acid (DHA)
• Reduced antioxidant capacity: Decreased GPX4 and system Xc⁻ activity
• Mitochondrial vulnerability: High mitochondrial lipid content
• Iron accumulation: Catalytic iron in proximity to membrane phospholipids

GPX4 and the Glutathione System

Glutathione Peroxidase 4 (GPX4)

GPX4 is the central enzyme preventing ferroptosis by reducing lipid hydroperoxides:

2GSH + LOOH → GSSG + H₂O + LOH (via GPX4 catalysis)

GPX4 requires:

• Glutathione (GSH): Substrate for the reaction
• Selenocysteine: Catalytic residue at active site

Evidence of GPX4 Dysfunction in PSP

• Reduced GPX4 expression: Decreased in PSP substantia nigra and globus pallidus
• GSH depletion: Reduced glutathione levels in PSP brain tissue
• Selenoprotein dysfunction: Altered expression of selenoprotein genes

System Xc⁻

The cystine/glutamate antiporter (system Xc⁻) provides cystine for GSH synthesis:

• SLC7A11: Catalytic subunit
• SLC3A2: Regulatory subunit (4F2hc)
• Activity reduction: Leads to cystine import failure and GSH depletion

Ferroptosis in Specific Cell Types

Neuronal Ferroptosis

Evidence in PSP:

• Iron accumulation in vulnerable neuronal populations
• 4-HNE adduct formation in neurons
• Reduced GPX4 expression in surviving neurons

• Tau pathology intersects with ferroptosis pathways
• Mitochondrial dysfunction promotes iron-dependent death
• Calcium dysregulation increases iron influx

Microglial Ferroptosis

Evidence in PSP:

• Iron-laden microglia (brain iron loading)
• Activated morphology with iron inclusions
• Cytokine release upon ferroptotic death

• Phagocytic overload of iron from dying neurons
• TLR signaling alters iron metabolism
• Ferroptosis may fuel neuroinflammation

Oligodendroglial Ferroptosis

Evidence in PSP:

• White matter degeneration correlates with oligodendrocyte loss
• Myelin basic protein reduction
• Iron accumulation in oligodendrocytes

• High lipid content makes oligodendrocytes vulnerable
• Myelin turnover requires iron-dependent processes
• Coiled body formation relates to ferroptotic stress

Molecular Cross-links with Tau Pathology

Tau-Ferroptosis Interactions

Tau pathology intersects with ferroptosis through multiple mechanisms: PMID: 36538378

Tau Phosphorylation and Ferroptosis

• GSK-3β activation: Iron stimulates GSK-3β, increasing tau phosphorylation at disease-relevant sites
• CDK5 dysregulation: Calcium-dependent activation affects tau pathology
• PP2A inhibition: Iron-mediated inhibition reduces tau dephosphorylation

Biomarkers of Ferroptosis

Blood-Based Biomarkers

| Biomarker | Source | Alteration in PSP |
|-----------|--------|-------------------|
| Iron (serum) | Blood | Variable, may be elevated |
| Ferritin | Blood | Elevated in some patients |
| 4-HNE | Plasma | Elevated |
| MDA | Plasma | Elevated |
| GPX4 activity | Blood cells | Reduced |

CSF Biomarkers

| Biomarker | Source | Alteration in PSP |
|-----------|--------|-------------------|
| 4-HNE | CSF | Elevated |
| F₂-isoprostanes | CSF | Elevated |
| Iron | CSF | Variable |
| Ferritin | CSF | May be elevated |
| 8-oxoguanosine | CSF | Elevated |

Neuroimaging Biomarkers

• Quantitative susceptibility mapping (QSM): Detects brain iron accumulation
• R2* mapping: Relates to iron concentration
• MRI relaxometry: Elevated R2 in basal ganglia

Therapeutic Implications

Iron Chelation Therapy

Chelators with potential in PSP:

| Agent | Mechanism | Evidence | Status |
|-------|-----------|----------|--------|
| Deferoxamine (DFO) | Iron chelation | Preclinical | Limited BBB penetration |
| Deferasirox (DFX) | Oral iron chelation | Phase 2 trials | Under investigation |
| Deferiprone (DFP) | Iron chelation | Crosses BBB | Clinical trials in PD/PSP |
| Clioquinol | Metal-protein attenuation | Phase 2 trials | Investigated in AD |

Antioxidant Approaches

Lipophilic antioxidants:

• Vitamin E (α-tocopherol): Lipid-soluble antioxidant
• Coenzyme Q10 (CoQ10): Mitochondrial antioxidant
• Ferrostatin-1: Experimental ferroptosis inhibitor

• Erastin: System Xc⁻ inhibitor (induces ferroptosis - research use)
• Sulforaphane: Upregulates system Xc⁻

GPX4-Enhancing Strategies

• Selenium supplementation: Supports selenoprotein synthesis
• GSH precursors: N-acetylcysteine (NAC)
• GPX4 activators: Direct pharmacological activation

Combined Approaches

Rational combination therapies for ferroptosis in PSP:

Cross-Disease Comparison: Ferroptosis in 4R-Tauopathies

The 4R-tauopathies share common features of tau pathology but differ substantially in their ferroptosis profiles. This section provides a comparative analysis across progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), globular glial tauopathy (GGT), and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).

Overview of Ferroptosis in Each 4R-Tauopathy

Progressive Supranuclear Palsy (PSP)

PSP demonstrates the most robust evidence for ferroptosis involvement among the 4R-tauopathies:

• Iron accumulation: Marked iron deposition in the [globus pallidus internus](/brain-regions/globus-pallidus), [subthalamic nucleus](/cell-types/subthalamic-nucleus-psp), and [substantia nigra pars reticulata](/cell-types/substantia-nigra-neurons-progressive-supranuclear-palsy) ([Gomez et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34187692/))
• Lipid peroxidation: Elevated 4-hydroxynonenal (4-HNE), malondialdehyde (MDA), and F₂-isoprostanes in brain tissue and CSF
• GPX4 dysfunction: Reduced GPX4 expression in substantia nigra and globus pallidus
• System Xc⁻ alterations: Decreased SLC7A11 expression affecting glutathione synthesis

Corticobasal Degeneration (CBD)

CBD shares similar ferroptosis mechanisms with PSP but with notable differences:

• Iron accumulation: Prominent iron deposition in basal ganglia, particularly the [globus pallidus](/brain-regions/globus-pallidus) and [putamen](/brain-regions/putamen), though generally less severe than PSP ([Zhang et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35837364/))
• Regional distribution: Iron accumulation correlates with asymmetric cortical and basal ganglia pathology
• Cell-type vulnerability: Both neurons and astrocytes show iron-related stress, with astrocytic plaques showing 4-HNE immunoreactivity
• Lipid peroxidation: Evidence of lipid peroxidation in affected regions, though less characterized than in PSP

Argyrophilic Grain Disease (AGD)

AGD shows the weakest ferroptosis evidence among 4R-tauopathies:

• Iron accumulation: Minimal iron deposition compared to PSP and CBD; argyrophilic grains themselves do not contain significant iron ([Elsockopp et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35439876/))
• Lipid peroxidation: Limited data on lipid peroxidation markers in AGD
• Therapeutic implications: May indicate less ferroptosis-driven pathogenesis, suggesting different therapeutic targets

Globular Glial Tauopathy (GGT)

GGT presents unique ferroptosis considerations due to its predominant glial pathology:

• Iron accumulation: White matter iron deposition corresponding to regions of [globular oligodendroglial inclusions](/diseases/globular-glial-tauopathy) (GOIs) ([Ahmed et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23400634/))
• Oligodendroglial vulnerability: High lipid content in [oligodendrocytes](/cell-types/oligodendrocytes) makes them particularly susceptible to ferroptosis
• Myelin degeneration: Iron-catalyzed lipid peroxidation may contribute to the severe white matter loss characteristic of GGT
• Astrocytic involvement: [Globular astroglial inclusions](/diseases/globular-glial-tauopathy) (GAIs) may show iron-related stress

FTDP-17 (MAPT Mutations)

FTDP-17 caused by [MAPT](/genes/mapt) mutations provides genetic insights into ferroptosis:

• Tau mutations and iron: Certain MAPT mutations (e.g., P301L, V337M) may alter tau's iron-binding capacity, potentially modulating ferroptosis susceptibility ([Bachetti et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35893741/))
• Genetic variability: Variable ferroptosis profiles depending on specific mutation
• Therapeutic relevance: MAPT mutation carriers may benefit from ferroptosis-targeted interventions

Comparative Table: Ferroptosis Markers Across 4R-Tauopathies

| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| Iron accumulation (severity) | +++ | ++ | + | ++ | Variable |
| GPX4 dysfunction | +++ | ++ | ? | ++ | Variable |
| Lipid peroxidation (4-HNE/MDA) | +++ | ++ | + | ++ | Variable |
| System Xc⁻ (SLC7A11) | ↓↓ | ↓ | ? | ↓ | Variable |
| Neuronal ferroptosis | +++ | ++ | + | + | ++ |
| Glial ferroptosis (oligo/astro) | ++ | ++ | + | +++ | + |
| Therapeutic target potential | High | High | Low | Moderate | Variable |

Legend: +++ = strong, ++ = moderate, + = mild, ? = unknown, ↓ = decreased

GPX4 Alterations Across 4R-Tauopathies

Glutathione peroxidase 4 (GPX4) is the central enzymatic defender against ferroptosis. Its status varies across 4R-tauopathies: PMID: 37454645

PSP: Most severe GPX4 dysfunction

• Markedly reduced GPX4 expression in vulnerable neurons
• Decreased activity in substantia nigra and globus pallidus
• Selenocysteine incorporation defects affecting catalytic function

• Reduced GPX4 in affected cortical and basal ganglia regions
• Similar but less severe than PSP patterns

• Oligodendrocyte GPX4 vulnerability due to high lipid content
• May contribute to myelin degeneration

• Limited published data on GPX4 status

ACSL4 in 4R-Tauopathies

Acyl-CoA synthetase long-chain family member 4 (ACSL4) is a key enzyme that promotes ferroptosis by incorporating polyunsaturated fatty acids into phospholipids. Its role in 4R-tauopathies is emerging:

ACSL4 and Ferroptosis Sensitivity

• ACSL4 catalyzes the conversion of arachidonic acid (AA) and adrenic acid (AdA) to their CoA esters
• These fatty acid-CoA esters are incorporated into phosphatidylethanolamine (PE), generating PE-AA and PE-AdA
• These PE species are highly susceptible to peroxidation, promoting ferroptosis ([Doll et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28193842/))

• PSP: Increased ACSL4 expression in affected brain regions may heighten ferroptosis susceptibility
• CBD: Similar ACSL4 upregulation patterns
• Therapeutic targeting: ACSL4 inhibitors (e.g., rosiglitazone, pioglitazone) may reduce ferroptosis sensitivity

• Thiazolidinediones (TZDs): FDA-approved drugs that inhibit ACSL4
• Potential for repurposing in 4R-tauopathies ([Behrens et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36194123/))

NCOA4-Mediated Ferritinophagy in 4R-Tauopathies

NCOA4 (Nuclear Receptor Coactivator 4) is a cargo receptor that delivers ferritin to lysosomes through autophagy (ferritinophagy), releasing iron for cellular use. Dysregulation of this pathway contributes to ferroptosis:

Ferritinophagy Mechanism

NCOA4 in 4R-Tauopathies

PSP: Elevated ferritinophagy

• Increased NCOA4 expression in affected neurons
• Enhanced ferritin degradation releases iron, promoting ferroptosis
• Ferritin accumulation in microglia suggests ongoing iron turnover from dying neurons

• NCOA4-mediated iron release contributes to cellular stress
• May explain the iron accumulation in affected regions

• Ferritinophagy inhibitors: Could reduce iron release and ferroptosis
• Autophagy inhibitors: Chloroquine, hydroxychloroquine may modulate ferritinophagy
• Iron sequestration: Enhancing ferritin expression may buffer labile iron

Lipid Peroxidation Patterns Across 4R-Tauopathies

The lipid peroxidation cascade varies in intensity and pattern:

4-Hydroxynonenal (4-HNE)

• PSP: Highest levels, extensive protein adduct formation
• CBD: Moderate elevation in affected regions
• GGT: Prominent in white matter oligodendrocytes
• AGD: Lower levels, limited adduct formation

• PSP: Markedly elevated in brain tissue and CSF
• CBD: Elevated but less pronounced
• GGT: Elevated in white matter regions
• AGD: Limited data

• PSP: Significantly elevated in CSF
• CBD: Elevated in both brain tissue and CSF
• Other 4R-tauopathies: Less characterized

Therapeutic Implications

The cross-disease comparison reveals opportunities for personalized ferroptosis-targeted therapy:

High Priority (PSP, CBD)

• Iron chelation (deferiprone, deferasirox)
• GPX4-enhancing strategies (selenium, NAC)
• ACSL4 inhibition (thiazolidinediones)

• White matter-targeted interventions
• Oligodendrocyte protection
• Autophagy modulation

• May not benefit significantly from ferroptosis-targeted therapy
• Focus on other mechanisms (tau pathology, neuroinflammation)

• Genotype-specific approaches
• Mutation-specific ferroptosis modulation

Research Directions

Unresolved Questions

Emerging Research Areas

• GPX4-targeted therapeutics: Small molecule activators
• ACSL4 inhibitors: Repurposing thiazolidinediones
• NCOA4 modulation: Autophagy-targeted approaches
• Lipidomics: Mapping specific lipid species vulnerable to peroxidation
• Ferroptosis imaging: PET ligands for in vivo detection
• Genetic modifiers: Identifying ferroptosis-related genetic variants

Cross-Disease Conclusions

Ferroptosis represents a significant mechanism across the 4R-tauopathy spectrum, with PSP and CBD showing the strongest evidence for iron-dependent cell death. GGT presents unique considerations due to its predominant glial pathology, while AGD appears less ferroptosis-driven. FTDP-17 provides genetic models for understanding tau-iron interactions. Targeting ferroptosis through iron chelation, antioxidant strategies, and lipid metabolism modulation offers promising therapeutic approaches, particularly for PSP and CBD. PMID: 38744613

Conclusions

Ferroptosis represents a significant, underexplored mechanism in PSP pathogenesis. The disease's characteristic iron accumulation in vulnerable brain regions, combined with evidence of lipid peroxidation and antioxidant system alterations, provides a strong rationale for ferroptosis involvement. The intersection of tau pathology with iron-dependent cell death pathways suggests potential therapeutic targeting of this mechanism.

References

Cross-References

• [Iron Accumulation in PSP](/mechanisms/iron-accumulation-psp)
• [PSP Mitochondrial Dysfunction](/mechanisms/psp-mitochondrial-dysfunction)
• [PSP Neuroinflammation](/mechanisms/neuroinflammation-psp)
• [Cell Death in 4R-Tauopathies](/mechanisms/cell-death-4r-tauopathies)
• [4R-Tauopathy Brain Region Vulnerability](/mechanisms/4r-tauopathy-regional-vulnerability)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease)
• [Globular Glial Tauopathy](/diseases/globular-glial-tauopathy)
• [FTDP-17 Genetics](/diseases/ftdp-17)
• [GPX4 Protein](/proteins/gpx4-protein)
• [ACSL4 Protein](/proteins/acsl4-protein)
• [NCOA4 Protein](/proteins/ncoa4-protein)